A Comprehensive Biological and Synthetic Perspective on 2-Deoxy-d-Glucose (2-DG), A Sweet Molecule with Therapeutic and Diagnostic Potentials.

J Med Chem

Department of Science, Faculty of Science and Technology, Alliance University, Chikkahagade Cross, Chandapura-Anekal Main Road, Anekal, Bengaluru 562106, Karnataka, India.

Published: March 2022

Glucose, the primary substrate for ATP synthesis, is catabolized during glycolysis to generate ATP and precursors for the synthesis of other vital biomolecules. Opportunistic viruses and cancer cells often hijack this metabolic machinery to obtain energy and components needed for their replication and proliferation. One way to halt such energy-dependent processes is by interfering with the glycolytic pathway. 2-Deoxy-d-glucose (2-DG) is a synthetic glucose analogue that can inhibit key enzymes in the glycolytic pathway. The efficacy of 2-DG has been reported across an array of diseases and disorders, thereby demonstrating its broad therapeutic potential. Recent approval of 2-DG in India as a therapeutic approach for the management of the COVID-19 pandemic has brought renewed attention to this molecule. The purpose of this perspective is to present updated therapeutic avenues as well as a variety of chemical synthetic strategies for this medically useful sugar derivative, 2-DG.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.1c01737DOI Listing

Publication Analysis

Top Keywords

2-deoxy-d-glucose 2-dg
8
glycolytic pathway
8
2-dg
5
comprehensive biological
4
biological synthetic
4
synthetic perspective
4
perspective 2-deoxy-d-glucose
4
2-dg sweet
4
sweet molecule
4
therapeutic
4

Similar Publications

Background: biomarkers are essential in order to make a diagnosis with a high level of accuracy in patients with cognitive and behavior complaints. However, molecular imaging biomarkers not always provide an answer in daily clinical practice.

Methods: retrospective and descriptive study in patients with Amyloid PET (APscans) implemented according to rational use of this technic, between January 2019-November 2023 in Neurology Department, Infanta Leonor Hospital, Madrid, Spain.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.

Background: Alzheimer's Disease (AD) has a long preclinical stage, in which brain metabolic alterations precede the symptoms onset. Therefore, an early and proper diagnosis of AD is essential for prevention and therapeutic evaluation. Current diagnosis and staging procedures rely on neuroimaging techniques, such as positron emission tomography (PET), which require intensity normalization to ensure the correct interpretation of the data.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Background: Many proposed clinical decision support systems (CDSS) require multiple disparate data elements as input, which makes implementation difficult, and furthermore have a black-box nature leading to low interpretability. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is an established modality for the diagnosis of dementia, and a CDSS that uses only an FDG-PET image to produce a reliable and understandable result would ease both of these challenges to clinical application.

Method: A deep variational autoencoder (VAE) was used to extract a latent representation of each image through prior training from FDG-PET brain images (n=2000).

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Sorbonne Université, Paris Brain Institute (ICM), INSERM, CNRS, UMR-1127, Mov'It, DreamTeam, Paris, France.

Background: Spectral power of slow rhythms in resting-state EEG increases along Alzheimer's disease (AD) continuum. Besides, recent studies have revealed 1) the importance of analyzing the aperiodic component of an EEG power spectrum and 2) the intrusions of sleep-like slow waves identifiable in wake EEG of animals and young adults. Importantly, the occurrence of these wake slow waves is known i) to increase after sleep deprivation, ii) to be associated with markers of sleepiness, and iii) to predict behavioral errors at different tasks.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.

Background: [F]FDG PET is essential since it allows us to differentiate between different dementia disorders/types, revealing distinct neurodegenerative patterns in those predisposed to the condition. Individuals with Autosomal Dominant Alzheimer's Disease (ADAD) have a predictable age of onset, enabling the study of cognitive and pathological changes before clinical manifestation. Our objective was to investigate temporal course and regional links between cognition and glucose metabolism as a measure of early synaptic impairment in ADAD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!